Trial · NCT03953300
Registered outcomes38
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 38
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The change in eosinophil numbers expressed as number/mm2 in submucosa as measured by major basic protein (MBP) staining in endobronchial biopsies | From baseline to Week 48 (Visit 10) | The change in eosinophil numbers expressed as number/mm2 in submucosa as measured by major basic protein (MBP) staining in endobronchial biopsies |
| Primary | The change in airway wall area percentage as the overall median for airway generations 3 and 4 combined as measured by quantitative computed tomography (QCT) imaging | From baseline to Week 48 (Visit 10) | The change in airway wall area percentage as the overall median for airway generations 3 and 4 combined as measured by quantitative computed tomography (QCT) imaging |
| Secondary | The change in eosinophil numbers, expressed as number/mm2 in epithelium as measured by major basic protein (MBP) staining in endobronchial biopsies | From baseline to Week 48 (Visit 10) | The change in eosinophil numbers, expressed as number/mm2 in epithelium as measured by major basic protein (MBP) staining in endobronchial biopsies |
| Secondary | The change in eosinophil numbers, expressed as number/mm2 in epithelium and submucosa as measured by major basic protein (MBP) staining in endobronchial biopsies | From baseline to Week 48 (Visit 10) | The change in eosinophil numbers, expressed as number/mm2 in epithelium and submucosa as measured by major basic protein (MBP) staining in endobronchial biopsies |
| Secondary | Absolute change in air trapping of the lung with expiratory density less than -856 Hounsfield Units (HU), and as expiratory-to-inspiratory ratio of mean lung density on computed tomography (CT) scans | From baseline to Week 48 (Visit 10) | Absolute change in air trapping of the lung with expiratory density less than -856 Hounsfield Units (HU), and as expiratory-to-inspiratory ratio of mean lung density on computed tomography (CT) scans |
| Secondary | Absolute change in air trapping/small airway obstruction derived from regional matching of the inspiratory/expiratory computed tomography (CT) scans | From baseline to Week 48 (Visit 10) | Absolute change in air trapping/small airway obstruction derived from regional matching of the inspiratory/expiratory computed tomography (CT) scans |
| Secondary | Change in airway lumen volume and airway resistance as measured by quantitative computed tomography (QCT) | From baseline to Week 48 (Visit 10) | Change in airway lumen volume and airway resistance as measured by quantitative computed tomography (QCT) |
| Secondary | Change in endobronchial biopsies on airway epithelial cell integrity | From baseline to Week 48 (Visit 10) | Change in endobronchial biopsies on airway epithelial cell integrity |
| Secondary | Change in endobronchial biopsies on reticular basement membrane (RBM) thickening | From baseline to Week 48 (Visit 10) | Change in endobronchial biopsies on reticular basement membrane (RBM) thickening |
| Secondary | Change in endobronchial biopsies on vascularization of the sub-mucosa | From baseline to Week 48 (Visit 10) | Change in endobronchial biopsies on vascularization of the sub-mucosa |
| Secondary | Assessments of peripheral airway resistance measured by AO | From baseline to Week 48 (Visit 10) | Assessments of peripheral airway resistance measured by AO |
| Secondary | Change in endobronchial biopsies on mucin 5AC, oligomeric mucus/gel-forming (MUC5AC) | From baseline to Week 48 (Visit 10) | Change in endobronchial biopsies on mucin 5AC, oligomeric mucus/gel-forming (MUC5AC) |
| Secondary | Absolute change in R5-R20 (peripheral airway resistance defined as the difference in resistance between 5 Hz [R5, total respiratory system resistance] and 20 Hz [R20, central resistance]) as measured by airwave oscillometry (AO) | From baseline to Week 48 (Visit 10) | Absolute change in R5-R20 (peripheral airway resistance defined as the difference in resistance between 5 Hz \[R5, total respiratory system resistance\] and 20 Hz \[R20, central resistance\]) as measured by airwave oscillometry (AO) |
| Secondary | Absolute change in area under the reactance curve (AX) as measured by airwave oscillometry (AO) | From baseline to Week 48 (Visit 10) | Absolute change in area under the reactance curve (AX) as measured by airwave oscillometry (AO) |
| Secondary | Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) residual volume (RV) | From baseline to Week 48 (Visit 10) | Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) residual volume (RV) |
| Secondary | Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) total lung capacity (TLC) | From baseline to Week 48 (Visit 10) | Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) total lung capacity (TLC) |
| Secondary | Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) inspiratory capacity (IC) | From baseline to Week 48 (Visit 10) | Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) inspiratory capacity (IC) |
| Secondary | Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) RV/TLC ratio | From baseline to Week 48 (Visit 10) | Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) residual volume / total lung capacity (RV/TLC) ratio |
| Secondary | Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP)functional residual capacity (FRC) | From baseline to Week 48 (Visit 10) | Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP)functional residual capacity (FRC) |
| Secondary | Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) vital capacity (VC) | From baseline to Week 48 (Visit 10) | Absolute change in pre-bronchodilator (BD) whole body plethysmogrpahy (WBP) vital capacity (VC) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03953300/registered